Establishment Labs Holdings Inc (DE:3E0)
FRANKFURT:3E0
Earnings Data
Report Date
Aug 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.29Last Year’s EPS
-0.49Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated strong operational and commercial momentum led by a rapid U.S. launch, 45% YoY revenue growth in Q1, improving gross margin (70.7%) and a return to positive adjusted EBITDA. Key product innovations (minimally invasive platform) are driving adoption, surgeon and patient demand, and management raised full-year revenue guidance. Offsetting factors include elevated operating expenses, near-term cash usage and increased debt with PIK mechanics, plus some supply and geopolitical uncertainties. Overall, the positives around revenue acceleration, margin expansion, product differentiation and pathway to cash-flow positivity materially outweigh the risks discussed.Company Guidance
Strong Top-Line Growth
Q1 2026 revenue of $59.9M, up 44.7% YoY (management rounded to 45%), with full-year guidance raised to $266.5M–$268.5M (≈26%–27% growth vs. 2025).
U.S. Outperformance and Rapid Launch Traction
U.S. revenue of $19.6M in Q1 (32.7% of total), up 216% YoY and +13.3% QoQ; U.S. expected to exceed 30% of total revenue for 2026 (vs ~22% in 2025). Company reported new weekly highs in U.S. order counts and a 30% increase in average orders since end of Q4.
Minimally Invasive Platform Momentum
Minimally invasive platform generated $9.1M in Q1; management raised 2026 guidance for this business to exceed $35M (up from prior $30M). More than 260 U.S. surgeons certified (surpassed plan of 200 for 2026 early). Preserve patient survey: 98% reported minimal disruption, 95% satisfied, 15% were new to category, 84% willing to pay a premium and 99% would choose the procedure again.
Improving Profitability Metrics
Gross margin expanded by 350 bps to 70.7% in Q1 2026 (from 67.2% in Q1 2025). Adjusted EBITDA positive $1.2M in Q1 versus loss of $12.1M in Q1 2025 — third consecutive quarter of positive adjusted EBITDA and company expects adjusted EBITDA positive each quarter in 2026.
Operational Scale and Market Adoption
Surpassed 1,700 accounts globally; 78% of surgeons report being asked for a brand by name and Motiva is requested 93% of the time in those instances. Company reported a 30% increase in average orders since end of Q4 and faster adoption by higher-volume surgeons.
Strong Clinical / Safety Data and Market Differentiation
FDA clinical trial and global post-market data show device-related complication rates at new industry lows (<1% capsular contracture and <1% claim rate from >49,000 warranties sold with 377 claims). Management contrasted this to competitor device-related complication rates up to ~20% in FDA trials.
Balance Sheet Actions and Liquidity Management
Refinanced debt (increase in facility availability from $225M to $265M) with a lower stated rate (8.75%) and PIK option to support near-term cash; received ~$6M proceeds from refinancing in the quarter and management believes they have enough cash to reach cash flow positive in H2 2026 (cash on hand $68.1M at quarter end).
Broader R&D and Market Expansion Pipeline
Submitted Motiva implants for U.S. FDA approval in breast reconstruction (Dec 2025) to expand addressable market; CE Mark for Zen temperature biosensing; ongoing pipeline items include Ergo2, GEM (gluteal augmentation), smaller sizes and Health Canada submission plans.
DE:3E0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:3E0 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | €59.30 | €64.00 | +7.93% |
Feb 24, 2026 | €63.50 | €61.00 | -3.94% |
Nov 05, 2025 | €37.60 | €37.60 | 0.00% |
Aug 07, 2025 | €37.20 | €32.80 | -11.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Establishment Labs Holdings Inc (DE:3E0) report earnings?
Establishment Labs Holdings Inc (DE:3E0) is schdueled to report earning on Aug 11, 2026, Before Open (Confirmed).
What is Establishment Labs Holdings Inc (DE:3E0) earnings time?
Establishment Labs Holdings Inc (DE:3E0) earnings time is at Aug 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Establishment Labs Holdings Inc stock?
The P/E ratio of Establishment Labs Holdings is N/A.
What is DE:3E0 EPS forecast?
DE:3E0 EPS forecast for the fiscal quarter 2026 (Q2) is -0.29.